We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
- Authors
Murashige, Naoko; Kami, Masahiro; Kishi, Yukiko; Sung-Won Kim; Takeuchi, Masami; Matsue, Kosei; Kanda, Yoshinobu; Hirokawa, Makoto; Kawabata, Yoshinari; Matsumura, Tomoko; Kusumi, Eiji; Hirabayashi, Noriyuki; Nagafuji, Koji; Suzuki, Ritsuro; Takeuchi, Kengo; Oshimi, Kazuo
- Abstract
The efficacy of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) for natural killer (NK)-cell neoplasms is unknown. We investigated the results of allo-HSCT for NK-cell neoplasms between 1990 and 2003 through questionnaires. After reclassification by a haematopathologist, of 345 patients who underwent allo-HSCT for malignant lymphoma, 28 had NK-cell neoplasms (World Health Organization classification): extranodal NK/T-cell lymphoma ( n = 22), blastic NK-cell lymphoma ( n = 3), and aggressive NK-cell leukaemia ( n = 3). Twelve were chemosensitive and 16 chemorefractory. Twenty-two had matched-related donors. Stem-cell source was bone marrow in eight and mobilised peripheral blood in 20. Conditioning regimens were myeloablative ( n = 23) and non-myeloablative ( n = 5). Grade 2–4 acute graft- versus-host disease (GVHD) and chronic GVHD developed in 12 and 8 respectively. Eight died of disease progression, three of infection, two of acute GVHD, one of veno-occlusive disease, one of interstitial pneumonitis, and one of thrombotic microangiopathy. Two-year progression-free and overall survivals were 34% and 40% respectively (median follow-up, 34 months). All patients who did not relapse/progress within 10 months achieved progression-free survival (PFS) during the follow-up. In multivariate analysis, stem cell source (BM versus peripheral blood; relative risk 3·03), age (≥40 years vs. <40 years; relative risk 2·85), and diagnoses (extranodal NK/T-cell lymphoma versus others; relative risk 3·94) significantly affected PFS. Allo-HSCT is a promising treatment for NK-cell neoplasms.
- Subjects
STEM cell transplantation; KILLER cells; TUMORS; HOMOGRAFTS; HEMATOPOIETIC stem cells; BONE marrow cells; HEMATOLOGY
- Publication
British Journal of Haematology, 2005, Vol 130, Issue 4, p561
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2005.05651.x